BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26137406)

  • 1. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.
    Ahmed M; Cheng M; Cheung IY; Cheung NK
    Oncoimmunology; 2015 Apr; 4(4):e989776. PubMed ID: 26137406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Cheng M; Ahmed M; Xu H; Cheung NK
    Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
    Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
    J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
    Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
    Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.
    Nakajima M; Guo HF; Hoseini SS; Suzuki M; Xu H; Cheung NV
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28971. PubMed ID: 33844437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
    Park JA; Cheung NV
    J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
    Hoseini SS; Dobrenkov K; Pankov D; Xu XL; Cheung NK
    Oncoimmunology; 2017; 6(6):e1320625. PubMed ID: 28680755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.
    Cheng M; Santich BH; Xu H; Ahmed M; Huse M; Cheung NK
    Oncoimmunology; 2016 Jun; 5(6):e1168557. PubMed ID: 27471647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency.
    Wang L; Hoseini SS; Xu H; Ponomarev V; Cheung NK
    Cancer Immunol Res; 2019 Dec; 7(12):2013-2024. PubMed ID: 31615814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
    Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.
    Rosenkrans ZT; Erbe AK; Clemons NB; Feils AS; Medina-Guevara Y; Jeffery JJ; Barnhart TE; Engle JW; Sondel PM; Hernandez R
    bioRxiv; 2024 May; ():. PubMed ID: 38853889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
    Lin TY; Park JA; Long A; Guo HF; Cheung NV
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34497115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.